AMG 595

Drug Profile

AMG 595

Alternative Names: Anti-EGFRvIII-DM1 immunoconjugate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Anaplastic astrocytoma; Glioblastoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Recurrent) in Australia (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Recurrent) in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top